A new funding initiative launched by the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) and the Ann Theodore Foundation (ATF) aims to accelerate research into potential treatments for sarcoidosis, a complex inflammatory disease. The program, known as the ATF Sarcoidosis Inhibitor of mTOR (SIM), will provide up to $575,000 over two years to support a Phase 2 clinical trial investigating the effectiveness of mTOR inhibitors in treating cutaneous sarcoidosis – sarcoidosis affecting the skin.
Sarcoidosis is characterized by the formation of abnormal clusters of immune cells, known as granulomas, in various organs. Whereas the lungs are most frequently affected, approximately one-quarter of individuals with sarcoidosis experience symptoms in the skin. These symptoms can range from painful rashes and skin lesions to subcutaneous growths. Currently, treatment options primarily focus on managing symptoms with general anti-inflammatory medications, addressing the need for therapies that target the underlying causes of the disease.
The ATF-SIM program represents a strategic effort to reverse a historical pattern of limited funding for sarcoidosis research. This new funding builds on previous collaborations between the Milken Institute and the Ann Theodore Foundation, including the ATF-LOMAS (Learning Opportunities in Medicine and Sarcoidosis) and ATF-BSI (Breakthrough Sarcoidosis Initiative) programs, which have collectively committed over $11 million to sarcoidosis research since 2020. The organizations also collaborated on a “Giving Smarter Guide” to identify strategic investment opportunities in the field.
Promising Early Results Fuel New Trial
The focus on mTOR inhibitors stems from encouraging preliminary findings. A small clinical trial conducted in 2024 suggested that sirolimus, an mTOR inhibitor already approved for other inflammatory conditions, showed significant promise in treating cutaneous sarcoidosis. According to the findings, seven out of ten participants experienced sustained improvement in their symptoms after completing treatment with sirolimus. This positive signal prompted the ATF and Milken Institute to prioritize a larger, more comprehensive clinical trial to validate these results.
“People living with sarcoidosis, which can be incredibly painful and unpredictable, don’t currently have the treatment options they deserve,” said Melissa Stevens, Executive Vice President of Strategic Philanthropy at the Milken Institute. “To advance this potential treatment toward late-stage clinical trials and regulatory approval for leverage in treating cutaneous sarcoidosis, researchers must continue to demonstrate that an mTOR inhibitor has a significant effect in a new trial with more participants. We are excited to operate with ATF to ensure the field takes this next step as quickly as possible.”
Funding Details and Application Process
The ATF-SIM program will award grants to independent biomedical researchers at qualifying institutions worldwide. Funding levels will vary depending on the project’s scope and design. Individual researchers can receive up to $460,000 over two years, while interdisciplinary teams – defined as collaborations between a sarcoidosis expert and a researcher from another relevant field, or a team combining basic science and clinical expertise – are eligible for up to $575,000 over the same period. Applications are being accepted until Monday, April 20, 2026, at 11:59 PM Eastern Time, with awardees expected to be selected in June 2026.
Lisa Spalding, a spokesperson for the Ann Theodore Foundation, emphasized the organization’s commitment to supporting research at all stages. “At ATF, we believe we owe the sarcoidosis community to support promising research directions at all stages of development, including this timely opportunity to accelerate a potential short-term treatment,” she stated. “ATF-SIM complements, but does not supplant, our parallel efforts to support early-stage biomedical research and the development of a long-term scientific community through two other grant programs, which will yield benefits for decades to approach.”
This multi-faceted approach – supporting both early-stage discovery and translational research like the ATF-SIM program – reflects a growing recognition of the need for sustained investment in sarcoidosis research to improve the lives of those affected by this challenging condition. The hope is that this collaborative effort will pave the way for more effective treatments and, a cure.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by sarcoidosis? Share your experiences and thoughts in the comments below.